Hypertransaminemia and methotrexate: Not always a toxic effect?;Hipertransaminemia y metotrexato: Es siempre un efecto toxico?

Revista Clinica Espanola

Volumn 198, Issue 12, 1998, Pages 822-824

  Montilla Morales, C ^a   Lopez Longo F J ^a   Moreno Zazo, M ^a   Monteagudo Saez I ^a   Moreno Garcia A C ^a   Carreno Perez L ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Liver toxicity; Methotrexate; Rheumatoid arthritis; Viral infection

Indexed keywords

AMINOTRANSFERASE; METHOTREXATE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LIVER TOXICITY; MALE; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HEPATITIS, TOXIC; HUMANS; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TRANSAMINASES;

EID: 0344573039     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weinblatt ME, Coblyn JS,Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818-822.
2. Weinstein A, Marlowe S, Korn J, Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis: long-term observations. Am J Med 1985; 79:331-337.
3. Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31:305-314.
4. Weinblatt ME. Methotrexate. En: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1988; 833-844.
5. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33:1.449-1.461.
6. Songsiridey N, Furst DE. Methotrexate: the rapidly acting drug. Clin Rheum 1990; 4:575-594.
7. Bolonga C, Viu P, Picot MC, Jorgensen C, Sany J. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997; 36:535-540.
8. Espinoza LR, Zakraoui L, Espinoza CG, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 12:872-877.
9. Tishler M, Caspi A, Rosenbach TO, et al. Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations. Ann Rheum Dis 1988; 47:654-659.
10. Weinblatt ME, Trentham DE, Fraser PA. et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31:167-175.
11. Sauvezie B, Dubost JJ, Garandeau A, Rampon S. Le méthotrexate dans la polyarthrite rhumatoïde. Revue de la littérature. Rev Rhum 1987; 54:607-615.
12. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29:822-831.
13. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17:1.628-1.635.
14. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective trial of methotrexate in the treatment or rheumatoid arthritis: 84-month update. Arthritis Rheum 1992; 35:129-137.
15. Tolman KG, Clegg DO, Lee RG, Ward JR. Methotrexate and the liver. J Rheumatol 1985; 12 (suppl):28-34.
16. Lally EV, Ho G. A review of methotrexate therapy in Reiter syndrome. Semin Arthritis Rheum 1985; 15:139-145.
17. Rothenberg RJ, Graziano FM, Grandone JT, et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988; 31:612-615.
18. Van den Hoogen FHJ, Boerbooms AMT, Van de Putte LBA. Methotrexate treatment in scleroderma. Am J Med 1989; 87:116-117.
19. Kremer JM. Alarcón GS, Lighfoot RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37:316-328.
20. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33:9-18.
21. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993; 36:795-803.
22. Andersen LS, Hansen EL, Knudsen JB, Wester JU, Hansen GV, Hansen TM. Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects. J Rheumatol 1997; 24:830-837.
23. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997; 36:1.196-1.204.
24. Bruguera M. Hepatopatias causadas por medicamentos y tóxicos. En: Farreras P, Rozman C, eds. Medicina interna. Barcelona: Ed Doyma, 1988; 296-300.
25. Garcia San Miguel M. Infecciones por herpesvirus. En: Farreras P, Rozman C, eds. Medicina interna. Barcelona: Ed Doyma, 1988; 2.299-2.314.
26. Aboguddah A, Stein HB, Philips P, et al. Herpes simplex hepatitis in a patient with psoriatic arthritis taking prednisone and methotrexate: report and review of the literature. J Rheumatol 1997; 18:1.406-1.412.
27. Kanick KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin N Am 1997; 23:955-967.